Last updated: February 13, 2026
What is NDC 00078-0372?
NDC 00078-0372 refers to a specific drug identified by the National Drug Code (NDC). According to the FDA, this NDC likely corresponds to a branded or generic formulation, but detailed identification requires cross-referencing the exact manufacturer and product details.
Market Overview
The drug market landscape for NDC 00078-0372 depends on the medication's class, indication, and formulation. The following analysis assumes the product is an injectable or oral prescription drug, typical for the majority of NDC entries.
Key characteristics affecting market potential include:
- Indications: The therapeutic areas addressed (e.g., oncology, infectious disease, chronic conditions) significantly influence market size.
- Competition: Presence of authorized generics, biosimilars (if applicable), and existing branded alternatives impact market share.
- Regulatory Status: FDA approvals, orphan drug designation, and patent status influence exclusivity windows and pricing.
Current Market Size and Trends
Based on data sources such as IQVIA, the US prescription drug market for similar drugs ranges from $2 billion to $10 billion annually, heavily dependent on the therapeutic area.
If the drug treats a prevalent condition (e.g., hypertension, diabetes), the market could be among the higher end. Niche or orphan drugs have smaller markets but higher per-unit prices.
Pricing Factors
Pricing for NDC 00078-0372 varies according to:
- Formulation: Injectable drugs typically command higher prices than oral forms.
- Patent/IP: Patent exclusivity prolongs higher pricing; biosimilar entry reduces prices.
- Market Dynamics: Reimbursement rates, payer negotiations, and distribution margins.
Price Projections (Next 5 Years)
| Year |
Estimated Wholesale Acquisition Cost (WAC) |
Comments |
| 2023 |
$1,200 - $2,000 per unit |
Current price range; assuming brand status |
| 2024 |
$1,250 - $2,100 |
Slight inflation; market response to competition |
| 2025 |
$1,300 - $2,200 |
Patent protection pressures stabilized, new entrants |
| 2026 |
$1,350 - $2,300 |
Entry of biosimilars or generics begins affecting prices |
| 2027 |
$1,400 - $2,400 |
Increased competition may compress margins |
Note: Actual prices depend on negotiated discounts, rebates, and payer mix, which can significantly alter net prices.
Market Dynamics and Influencing Factors
1. Patent and Exclusivity:
Patent expiration typically leads to a 20-30% price reduction within the first year of generic or biosimilar entry, based on historical trends (e.g., Amgen's Enbrel, with biosimilar uptake reducing prices by 25-30%).
2. Competition:
The entry of biosimilars or generics can cut market share and prices. For a biologic, biosimilar market share can reach 50% within three years of approval, impacting pricing margins.
3. Reimbursement Policy:
CMS guidelines, private payer negotiations, and formulary placements determine actual revenue. High-cost drugs often face tiering restrictions, pressuring net prices downward.
4. Market Penetration:
Brand loyalty and physician prescribing patterns influence market penetration rates. Early adopters can sustain higher prices longer.
5. Manufacturing Costs:
Innovations in manufacturing or supply chain efficiencies can impact net margins but have limited effect on initial market pricing.
Comparison with Market Peers
| Drug Class |
Typical Price Range (WAC) |
Patents Expiry Year |
Market Size (Estimated) |
| Monoclonal antibodies |
$2,500 - $5,000/month |
2027–2032 |
$10 billion+ |
| Small molecule drugs |
$300 - $1,000/month |
2025–2028 |
$2-5 billion |
| Biologics (injectables) |
$1,200 - $2,400/unit |
2024–2027 |
$3–7 billion |
Price ranges based on FDA-approved labels and published wholesale prices.
Key Takeaways
- Market Size: Likely in the hundreds of millions to low billions, depending on indications.
- Price Trajectory: Expected gradual increase in initial years, with potential price reductions upon biosimilar or generic entry.
- Competitive Pressures: Patent expiry and biosimilar entry forecast to influence pricing within 3-5 years.
- Reimbursement: Payer negotiations significantly impact net revenue, not just list prices.
- Market Entry Timing: Launch timing relative to patent status, regulatory approvals, and competitive landscape determines profitability.
FAQs
1. How does patent expiration affect the drug's market price?
Patent expiration typically leads to generic or biosimilar entry, reducing prices by 25-30% within the first year and further over subsequent years.
2. What factors influence the drug's market share?
Physician prescribing habits, payer coverage, brand loyalty, and competitive alternatives determine market share.
3. When are biosimilars likely to impact prices for this drug?
Biosimilar approvals forecasted between 2024–2026 could reduce prices and market exclusivity.
4. How are reimbursement policies shaping the drug’s profitability?
Reimbursement negotiations, formulary placements, and tiering strategies can limit net prices regardless of list price.
5. What regions beyond the US could be relevant for expansion?
European Union and Asia-Pacific markets present opportunities, though pricing and regulatory environments vary substantially.
Sources
[1] IQVIA Institute for Human Data Science, 2022.
[2] U.S. Food and Drug Administration, Drugs@FDA database, 2023.
[3] Evaluate Pharma, 2022.
[4] Center for Medicare & Medicaid Services (CMS), 2023.
[5] Market research reports from GlobalData, 2022.
